Pharmacokineticist
U.S. Food and Drug Administration
Sydney Stern, Ph.D., is a clinical pharmacology reviewer in the Division of Translational and Precision Medicine (DTPM) in the Office of Clinical Pharmacology at the FDA. She received her Master of Science in Clinical Research and her Ph.D. in Pharmaceutical Sciences at the University of Maryland Baltimore. During her Ph.D., she developed a small molecule dual activator to improve the bioactivation of cyclophosphamide, a prodrug, and protect cardiomyocytes against doxorubicin-induced toxicity in the treatment of breast cancer. She has extensive experience with in vitro/in vivo extrapolation, particularly with liver-based models and cocultures, and has led several big data projects in the rare disease space. Additionally, Sydney has led a pilot program, called From Cells to Communities, at University of Maryland Baltimore in collaboration with the Marlene and Stewart Greenbaum Comprehensive Cancer Center to enhance bidirectional learning of early-stage scientists and cancer patients. She has served on multiple committees and working groups for creating standardized guidelines for rare diseases such as tenosynovial giant cell tumor and collaborative efforts between physicians, scientists, and patients to improve clinical trial design and patient care.